oxidopamine has been researched along with Muscular Atrophy in 1 studies
Oxidopamine: A neurotransmitter analogue that depletes noradrenergic stores in nerve endings and induces a reduction of dopamine levels in the brain. Its mechanism of action is related to the production of cytolytic free-radicals.
oxidopamine : A benzenetriol that is phenethylamine in which the hydrogens at positions 2, 4, and 5 on the phenyl ring are replaced by hydroxy groups. It occurs naturally in human urine, but is also produced as a metabolite of the drug DOPA (used for the treatment of Parkinson's disease).
Muscular Atrophy: Derangement in size and number of muscle fibers occurring with aging, reduction in blood supply, or following immobilization, prolonged weightlessness, malnutrition, and particularly in denervation.
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 1 (100.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Choe, MA | 1 |
| An, GJ | 1 |
| Koo, BS | 1 |
| Jeon, S | 1 |
1 other study available for oxidopamine and Muscular Atrophy
| Article | Year |
|---|---|
Effect of DHEA on recovery of muscle atrophy induced by Parkinson's disease.
Topics: Animals; Corpus Striatum; Dehydroepiandrosterone; Extracellular Signal-Regulated MAP Kinases; Male; | 2011 |